Ribose

• HOMEOPATHIC INDICATIONS: Temporary relief of symptoms related to sugar, including fatigue, headaches, and nervousness.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.ICD-10: R51.9

DIRECTIONS: 10 drops under the tongue 3 to 6 times per day or as directed by a health professional. Consult a physician for use in children under 12 years of age.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. If pregnant or breast-feeding, ask a health professional before use. Tamper seal: Sealed for your protection. Do not use if seal is broken or missing.

Recent PubMed references pinned to Ribose as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• D-Ribose Glycation of Human High-Density Lipoprotein: Structural and Functional Alterations.
  International journal of molecular sciences · 2026 · Morresi C, Tomaso VD, Ricci G, et al.
  PMID 42196350DOI 10.3390/ijms27104370
• Horizontal Gene Transfers Underpin Ribose Heterotrophy and Central Carbon Metabolism Remodeling in Gloeobacteraceae.
  Genome biology and evolution · 2026 · Sudianto E, Baurain D, Cornet L, et al.
  PMID 42175760DOI 10.1093/gbe/evag127
• Atypical catabolite repression of Geobacillus kaustophilus iol operons in the presence of ribose.
  Microbiology (Reading, England) · 2026 · Yoshida KI, Fukui K, Osawa T, et al.
  PMID 42048241DOI 10.1099/mic.0.001702
• Inhibition of d-ribose-induced glycation of metalloprotein human myoglobin by bioactive quinones.
  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2026 · Liu JJ, Miao SD, Wang ZY, et al.
  PMID 41932083DOI 10.1016/j.saa.2026.127817
• Characterizing the Conformational Dynamics of the Ribose Transporter B Protein in Escherichia coli: Enhanced Sampling via Multiple Force Fields.
  Journal of chemical theory and computation · 2026 · Juraschko N, Rocha FK, Khalid S, et al.
  PMID 41739525DOI 10.1021/acs.jctc.5c02068
• Ribose Accumulation in Borate-Rich Prebiotic Environments.
  Astrobiology · 2026 · Takahashi Y, Kim HJ, Benner SA, et al.
  PMID 41693553DOI 10.1177/15311074261417882
• D-ribose-induced cytotoxicity in K562 cells: RBKS-dependent disruption of copper homeostasis and mitochondrial function.
  Free radical biology & medicine · 2026 · Zeying W, Houyu L, Zhongbin Y, et al.
  PMID 41651301DOI 10.1016/j.freeradbiomed.2026.01.062
• Phosphorothioate and 2'-Fluoro Ribose Substitution-Mediated Hydrophobic Effect Empowers RNA Probes for Highly Sensitive and Subtype-Selective miRNA Imaging.
  ACS nano · 2026 · Zhou Y, Fan Y, Zhang H, et al.
  PMID 41474128DOI 10.1021/acsnano.5c17740

The 10 most recently updated of 206 ClinicalTrials.gov registrations naming Ribose as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  Active not recruiting · Phase 2 · Interventional · 85 enrolled · Fusion Pharmaceuticals Inc.
  NCT06909825updated 2026-06-09
• A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
  Terminated · Phase 2 · Interventional · 77 enrolled · Regeneron Pharmaceuticals
  NCT04916002updated 2026-06-09
• Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer
  Withdrawn · Phase 1 · Interventional · 0 enrolled · University of Alabama at Birmingham
  NCT04149145updated 2026-06-05
• Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
  Recruiting · Phase 1 · Interventional · 50 enrolled · University of Colorado, Denver
  NCT06856499updated 2026-06-04
• An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
  Recruiting · Phase 2 · Interventional · 53 enrolled · University of Colorado, Denver
  NCT05887609updated 2026-06-04
• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
  Active not recruiting · Phase 2 · Interventional · 63 enrolled · EMD Serono Research & Development Institute, Inc.
  NCT06433219updated 2026-06-03
• Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
  Recruiting · Phase 1 · Phase 2 · Interventional · 695 enrolled · AstraZeneca
  NCT05417594updated 2026-06-02
• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
  Recruiting · Phase 1 · Interventional · 479 enrolled · Amgen
  NCT04221542updated 2026-05-29
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  Recruiting · Phase 2 · Interventional · 716 enrolled · Fudan University
  NCT05582499updated 2026-05-28
• Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours
  Recruiting · Phase 1 · Phase 2 · Interventional · 180 enrolled · AstraZeneca
  NCT07446855updated 2026-05-26

Frequently asked questions

What is Ribose used for?

According to FDA labeling, Ribose carries indications including: HOMEOPATHIC INDICATIONS: Temporary relief of symptoms related to sugar, including fatigue, headaches, and nervousness.** **These statements are based upon homeopathic principles. They have not been reviewed by the Food and Drug Administration.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.